DoubleChecks

What was claimed

84.4% of cancer patients taking Ivermectin & Mebendazole had their cancer completely disappear, shrink, or stop spreading after 6 months in massive peer-reviewed study

Our verdict

Needs caution

The study reports 84.4% clinical benefit, but that includes stable disease as well as regression or no evidence of disease. Only 48.4% reported no evidence of disease or regression, not 84.4%. The study included 197 initial participants, with only 122 completing follow-up (61.9% response rate). While peer-reviewed, this is a relatively small observational study, not a large randomized controlled trial. The authors conclude findings are 'hypothesis-generating' and support the need for randomized controlled trials.

All 3 AI systems agree11 sources citedChecked Aug 18, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

This was a massive peer-reviewed study

Misleading85%
1 AI checked

84.4% of cancer patients taking ivermectin & mebendazole had their cancer completely disappear, shrink, or stop spreading after 6 months in a massive peer‑reviewed study

Misleading92%
All 4 AIs agree

Study was peer-reviewed

Verified95%
1 AI checked

Verified against 11 sources

publichealthpolicyjournal.compubmed.ncbi.nlm.nih.govx.comsanarelab.sciencejillcarnahan.comsanarelab.scienceleadstories.comx.comexplore.openaire.eux.compccarx.com

Detailed Analysis

The core numbers are real, but the wording is misleading. The study is a prospective observational cohort with self-reported outcomes, not a “massive” controlled trial proving the drugs made cancer disappear. The 84.4% figure refers to clinical benefit, which includes stable disease, not just disappearance or shrinkage.[2] [7] [9]

Why this verdict

  • The core numbers are real, but the wording is misleading.
  • The study is a prospective observational cohort with self-reported outcomes, not a “massive” controlled trial proving the drugs made cancer disappear.
  • The 84.4% figure refers to clinical benefit, which includes stable disease, not just disappearance or shrinkage.[2] [7] [9]

Claims checked

This was a massive peer-reviewed study

Misleading88%
The paper was a prospective observational cohort of 197 patients, which is not a massive study in oncology. It was described as peer-reviewed in later indexing, but it was not a randomized controlled trial and had major design limits.[2] [7] [9]

This claim may mislead readers without added context.

84.4% of cancer patients taking ivermectin and mebendazole had their cancer completely disappear, shrink, or stop spreading after 6 months

Misleading97%
The study reports 84.4% clinical benefit, but that includes stable disease as well as regression or no evidence of disease. Only 48.4% reported no evidence of disease or regression, not 84.4%.[2] [9]

This claim may mislead readers without added context.

What other AI think

The 84.4% figure is accurate and the study is peer-reviewed, but the claim oversimplifies the findings and omits critical context. The study was observational with self-reported outcomes (not objective measurements), had a 61.9% follow-up rate, and the authors themselves state findings are "hypothesis-generating" requiring randomized controlled trials. The claim presents preliminary results as definitive without acknowledging these limitations.

Why this verdict

  • The 84.4% figure is accurate and the study is peer-reviewed, but the claim oversimplifies the findings and omits critical context.
  • The study was observational with self-reported outcomes (not objective measurements), had a 61.9% follow-up rate, and the authors themselves state findings are "hypothesis-generating" requiring randomized controlled trials.
  • The claim presents preliminary results as definitive without acknowledging these limitations.

Claims checked

This was a massive peer-reviewed study

Misleading85%
The study included 197 initial participants, with only 122 completing follow-up (61.9% response rate). While peer-reviewed, this is a relatively small observational study, not a large randomized controlled trial. The authors conclude findings are 'hypothesis-generating' and support the need for randomized controlled trials.

This claim may mislead readers without added context.

84.4% of cancer patients taking Ivermectin & Mebendazole had their cancer completely disappear, shrink, or stop spreading after 6 months

Misleading92%
The 84.4% figure is accurate, but the claim misrepresents the nature of the data. The study measured self-reported outcomes via digital surveys, not objective clinical assessments. The 84.4% includes disease stabilization (36.1%), not just disappearance or shrinkage. Only 48.4% reported the strongest outcomes (complete remission or regression).

This claim may mislead readers without added context.

Study was peer-reviewed

Verified95%
The study was peer-reviewed and published in Anticancer Research, a major international oncology journal of the International Institute of Anticancer Research.
The 84.4% figure comes from a recent prospective, real‑world observational cohort reporting a 6‑month “clinical benefit ratio” (no evidence of disease + regression + stable disease). However the study is not a randomized controlled trial, relied largely on self‑reported/heterogeneous data and has been critiqued for methodological limits, so the headline framing is misleading. The description also overstates size and strength of evidence.

Why this verdict

  • The 84.4% figure comes from a recent prospective, real‑world observational cohort reporting a 6‑month “clinical benefit ratio” (no evidence of disease + regression + stable disease).
  • However the study is not a randomized controlled trial, relied largely on self‑reported/heterogeneous data and has been critiqued for methodological limits, so the headline framing is misleading.
  • The description also overstates size and strength of evidence.

Claims checked

84.4% of cancer patients taking ivermectin & mebendazole had their cancer completely disappear, shrink, or stop spreading after 6 months in a massive peer‑reviewed study

Misleading92%
A 2026 prospective observational cohort reported an 84.4% "clinical benefit ratio" at ~6 months defined as NED (no evidence of disease) + regression + stable disease, but outcomes were self‑reported, the design was non‑randomized and heterogeneous, and the study is not "massive"; thus the claim is an overstatement of the evidence strength.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks